The RTO Compliance Trap: Headcount Is the Wrong Metric
Full-time mandates are producing bodies in chairs, not measurable gains, and the data on who leaves first is the number executives should be watching.
Full-time mandates are producing bodies in chairs, not measurable gains, and the data on who leaves first is the number executives should be watching.
The October 2025 shutdown erased a jobs report and barely dented the S&P 500. Here is the calm playbook if history repeats.
With $1.7B in cash and a Q4 sNDA plan, Cytokinetics just validated a major untreated corner of HCM.
McKesson’s $2.25bn Precision deal adds clinical research heft to its fast-growing oncology segment.
A BOJ hike to 1.25% changes the currency math after the Nikkei’s extraordinary run.
Falling crude is a margin gift for refiners and airlines. Here is how to hold energy exposure through the September 6 OPEC+ meeting.
Salesforce’s 23% surge deserves scrutiny on cRPO and Agentforce ARR, not the $5.90 EPS that investment gains inflated.
Russia’s export curbs and record refinery strikes keep diesel tight even as crude softens on Hormuz hopes.
Revenue of $96.2 billion and $108 billion Q3 guidance cleared every bar, but a gross-margin guide cut is where the real positioning question lives.
A divided Fed, a hawkish dissent bloc, and a chairman who refuses to telegraph moves: here is what investors should be preparing for before he speaks.